{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T07:06:40Z","timestamp":1777100800704,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s40273-023-01278-3","type":"journal-article","created":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T14:02:36Z","timestamp":1685455356000},"page":"999-1010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Economic Burden of Idiopathic Pulmonary Fibrosis in Spain: A Prospective Real-World Data Study (OASIS Study)"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-9528","authenticated-orcid":false,"given":"Maria Jesus","family":"Rodr\u00edguez-Nieto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esteban","family":"Cano-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana D.","family":"Romero Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Villar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Morros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alba","family":"Ramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Armengol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"issue":"6","key":"1278_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu G, Collard HR, Egan JJ, et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788\u2013824. https:\/\/doi.org\/10.1164\/rccm.2009-040GL.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"1278_CR2","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.arbr.2013.06.003","volume":"49","author":"A Xaubet","year":"2013","unstructured":"Xaubet A, Ancochea J, Bollo E, et al. Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis. Arch Bronconeumol. 2013;49(8):343\u201353. https:\/\/doi.org\/10.1016\/j.arbr.2013.06.003.","journal-title":"Arch Bronconeumol"},{"issue":"9","key":"1278_CR3","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","volume":"14","author":"MO Paterniti","year":"2017","unstructured":"Paterniti MO, Bi Y, Reki\u0107 D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2017;14(9):1395\u2013402. https:\/\/doi.org\/10.1513\/AnnalsATS.201606-458OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"1278_CR4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","volume":"37","author":"JW Song","year":"2011","unstructured":"Song JW, Hong SB, Lim CM, Koh Y, Kim DS. Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356\u201363. https:\/\/doi.org\/10.1183\/09031936.00159709.","journal-title":"Eur Respir J"},{"issue":"9807","key":"1278_CR5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TEJ King","year":"2011","unstructured":"King TEJ, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949\u201361. https:\/\/doi.org\/10.1016\/S0140-6736(11)60052-4.","journal-title":"Lancet"},{"issue":"22","key":"1278_CR6","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TEJ King","year":"2014","unstructured":"King TEJ, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1402582.","journal-title":"N Engl J Med"},{"issue":"22","key":"1278_CR7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382. https:\/\/doi.org\/10.1056\/NEJMoa1402584.","journal-title":"N Engl J Med"},{"issue":"1","key":"1278_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12931-019-1037-7","volume":"20","author":"M Kreuter","year":"2019","unstructured":"Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS\u00ae trials. Respir Res. 2019;20(1):71. https:\/\/doi.org\/10.1186\/s12931-019-1037-7.","journal-title":"Respir Res"},{"issue":"1","key":"1278_CR9","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","volume":"18","author":"M Kreuter","year":"2017","unstructured":"Kreuter M, Swigris J, Pittrow D, et al. Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. Respir Res. 2017;18(1):139. https:\/\/doi.org\/10.1186\/s12931-017-0621-y.","journal-title":"Respir Res"},{"issue":"150","key":"1278_CR10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0075-2018","volume":"27","author":"JJ Swigris","year":"2018","unstructured":"Swigris JJ, Brown KK, Abdulqawi R, et al. Patients\u2019 perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150): 180075.","journal-title":"Eur Respir Rev"},{"issue":"7","key":"1278_CR11","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s40273-018-0631-8","volume":"36","author":"A Diamantopoulos","year":"2018","unstructured":"Diamantopoulos A, Wright E, Vlahopoulou K, Cornic L, Schoof N, Maher TM. The burden of illness of idiopathic pulmonary fibrosis: a comprehensive evidence review. Pharmacoeconomics. 2018;36(7):779\u2013807.","journal-title":"Pharmacoeconomics"},{"key":"1278_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/2050-6511-15-63","volume":"15","author":"E Loveman","year":"2014","unstructured":"Loveman E, Copley VR, Colquitt JL, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol. 2014;15:63. https:\/\/doi.org\/10.1186\/2050-6511-15-63.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"5","key":"1278_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3111\/13696998.2012.680553","volume":"15","author":"HR Collard","year":"2012","unstructured":"Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829\u201335. https:\/\/doi.org\/10.3111\/13696998.2012.680553.","journal-title":"J Med Econ"},{"issue":"2","key":"1278_CR14","doi-asserted-by":"publisher","first-page":"00045","DOI":"10.1183\/23120541.00045-2017","volume":"4","author":"O Hilberg","year":"2018","unstructured":"Hilberg O, Bendstrup E, Ibsen R, L\u00f8kke A, Hyldgaard C. Economic consequences of idiopathic pulmonary fibrosis in Denmark. ERJ Open Res. 2018;4(2):00045\u20132017. https:\/\/doi.org\/10.1183\/23120541.00045-2017.","journal-title":"ERJ Open Res."},{"issue":"1","key":"1278_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-016-0168-6","volume":"16","author":"F Morell","year":"2016","unstructured":"Morell F, Esser D, Lim J, et al. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain: results of a Delphi Panel. BMC Pulm Med. 2016;16(1):1\u20139.","journal-title":"BMC Pulm Med"},{"issue":"4","key":"1278_CR16","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jpainsymman.2011.05.006","volume":"43","author":"X G\u00f3mez-Batiste","year":"2012","unstructured":"G\u00f3mez-Batiste X, Caja C, Espinosa J, et al. The Catalonia World Health Organization demonstration project for palliative care implementation: quantitative and qualitative results at 20 years. J Pain Symptom Manag. 2012;43(4):783\u201394. https:\/\/doi.org\/10.1016\/j.jpainsymman.2011.05.006.","journal-title":"J Pain Symptom Manag"},{"key":"1278_CR17","unstructured":"Gisbert R, Brosa M. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud. 2007. http:\/\/www.oblikue.com\/bddcostes\/. Accessed."},{"key":"1278_CR18","unstructured":"Consejo General de Colegios Oficiales de Farmac\u00e9uticos. Base de Datos de Medicamentos: Bot PLUS 2.0. 2017. https:\/\/botplusweb.portalfarma.com\/. Accessed."},{"key":"1278_CR19","unstructured":"FACUA. Estudio comparativo de las tarifas de los taxis de 52 ciudades espa\u00f1olas. 2018. https:\/\/www.facua.org\/es\/documentos\/estudio_tarifas_taxi_2018.pdf. Accessed."},{"key":"1278_CR20","unstructured":"Ministerio de Sanidad Consumo y Bienestar Social. Orden SCB\/45\/2019, de 22 de enero. Bolet\u00edn Oficial del Estado n\u00fam. 22. 2019. https:\/\/www.boe.es\/boe\/dias\/2019\/01\/25\/pdfs\/BOE-A-2019-856.pdf. Accessed 5 Mar 2019."},{"key":"1278_CR21","unstructured":"Ministerio de Sanidad Consumo y Bienestar Social. Instituto de Informaci\u00f3n Sanitaria. Registro de Altas 2017: CMBD. http:\/\/pestadistico.inteligenciadegestion.msssi.es\/publicoSNS\/comun\/DefaultPublico.aspx. Accessed 10 April 2023."},{"key":"1278_CR22","unstructured":"Instituto Nacional de estad\u00edstica. C\u00e1lculo de variaciones del \u00cdndice de Precios de Consumo (sistema IPC base 2021): enero 2019 a enero 2023. https:\/\/www.ine.es\/varipc\/verVariaciones.do;jsessionid=3D690670881EC9EE56C25F8CBD0A524A.varipc03?idmesini=1&anyoini=2019&idmesfin=1&anyofin=2023&ntipo=1&enviar=Calcular. Accessed 17 Mar 2019."},{"key":"1278_CR23","unstructured":"Instituto Nacional de Estad\u00edstica. Encuesta anual de estructura salarial (2017). Notas de prensa. 21 June 2019."},{"issue":"1","key":"1278_CR24","doi-asserted-by":"publisher","first-page":"1702618","DOI":"10.1080\/20018525.2019.1702618","volume":"7","author":"MI Lassenius","year":"2019","unstructured":"Lassenius MI, Toppila I, P\u00f6ntynen N, et al. Forced vital capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. Eur Clin Respir J. 2019;7(1):1702618. https:\/\/doi.org\/10.1080\/20018525.2019.1702618.","journal-title":"Eur Clin Respir J."},{"key":"1278_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/CEOR.S154323","volume":"10","author":"J-E Tarride","year":"2018","unstructured":"Tarride J-E, Hopkins RB, Burke N, et al. Clinical and economic burden of idiopathic pulmonary fibrosis in Quebec, Canada. Clinicoecon Outcomes Res. 2018;10:127\u201337. https:\/\/doi.org\/10.2147\/CEOR.S154323.","journal-title":"Clinicoecon Outcomes Res."},{"issue":"1","key":"1278_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12931-019-1084-0","volume":"20","author":"E Fern\u00e1ndez-Fabrellas","year":"2019","unstructured":"Fern\u00e1ndez-Fabrellas E, Molina-Molina M, Soriano JB, et al. Demographic and clinical profile of idiopathic pulmonary fibrosis patients in Spain: the SEPAR National Registry. Respir Res. 2019;20(1):127. https:\/\/doi.org\/10.1186\/s12931-019-1084-0.","journal-title":"Respir Res"},{"issue":"2","key":"1278_CR27","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1164\/rccm.201902-0431CI","volume":"200","author":"DA Culver","year":"2019","unstructured":"Culver DA, Behr J, Belperio JA, et al. Patient registries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2019;200(2):160\u20137. https:\/\/doi.org\/10.1164\/rccm.201902-0431CI.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1278_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","volume":"183","author":"B Ley","year":"2011","unstructured":"Ley B, Collard HR, King TEJ. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431\u201340. https:\/\/doi.org\/10.1164\/rccm.201006-0894CI.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1278_CR29","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1111\/crj.12700","volume":"12","author":"M Doubkov\u00e1","year":"2018","unstructured":"Doubkov\u00e1 M, \u0160vancara J, Svoboda M, et al. EMPIRE Registry, Czech Part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J. 2018;12(4):1526\u201335. https:\/\/doi.org\/10.1111\/crj.12700.","journal-title":"Clin Respir J"},{"issue":"1","key":"1278_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12890-018-0575-y","volume":"18","author":"HE Jo","year":"2018","unstructured":"Jo HE, Glaspole I, Moodley Y, et al. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry. BMC Pulm Med. 2018;18(1):19.","journal-title":"BMC Pulm Med"},{"key":"1278_CR31","unstructured":"Osakidetza. Tarifas para facturaci\u00f3n de servicios sanitarios y docentes de Osakidetza para el a\u00f1o 2020. Informe. 2019."},{"issue":"3","key":"1278_CR32","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.gaceta.2020.12.035","volume":"36","author":"O Ibarrondo","year":"2022","unstructured":"Ibarrondo O, Lizeaga G, Mart\u00ednez-Llorente JM, Larra\u00f1aga I, Soto-Gordoa M, \u00c1lvarez-L\u00f3pez I. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gac Sanit. 2022;36(3):246\u201352. https:\/\/doi.org\/10.1016\/j.gaceta.2020.12.035.","journal-title":"Gac Sanit"},{"issue":"3","key":"1278_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s12029-022-00821-3","volume":"36","author":"D Hernandez","year":"2022","unstructured":"Hernandez D, Wagner F, Hernandez-Villafuerte K, Schlander M. Economic burden of pancreatic cancer in Europe: a literature review. J Gastrointest Cancer. 2022;36(3):246\u201352. https:\/\/doi.org\/10.1007\/s12029-022-00821-3.","journal-title":"J Gastrointest Cancer"},{"issue":"4","key":"1278_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1136\/thoraxjnl-2016-208710","volume":"72","author":"M Kolb","year":"2017","unstructured":"Kolb M, Richeldi L, Behr J, et al. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017;72(4):340\u20136. https:\/\/doi.org\/10.1136\/thoraxjnl-2016-208710.","journal-title":"Thorax"},{"issue":"12","key":"1278_CR35","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMoa1103690","volume":"365","author":"L Richeldi","year":"2011","unstructured":"Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365(12):1079\u201387. https:\/\/doi.org\/10.1056\/NEJMoa1103690.","journal-title":"N Engl J Med"},{"key":"1278_CR36","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","volume":"113","author":"L Richeldi","year":"2017","unstructured":"Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. Respir Med. 2017;113:74\u20139. https:\/\/doi.org\/10.1016\/j.rmed.2016.02.001.","journal-title":"Respir Med"},{"issue":"9","key":"1278_CR37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S2213-2600(19)30255-3","volume":"7","author":"TM Maher","year":"2019","unstructured":"Maher TM, Stowasser S, Nishioka Y, et al. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. Lancet Respir Med. 2019;7(9):771\u20139. https:\/\/doi.org\/10.1016\/S2213-2600(19)30255-3.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"1278_CR38","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.3390\/ijerph18031101","volume":"18","author":"P Armeni","year":"2021","unstructured":"Armeni P, Cavazza M, Xoxi E, Taruscio D, Kodra Y. Reflections on the importance of cost of illness analysis in rare diseases: a proposal. Int J Environ Res Public Health. 2021;18(3):1101. https:\/\/doi.org\/10.3390\/ijerph18031101.","journal-title":"Int J Environ Res Public Health"},{"issue":"1","key":"1278_CR39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12890-017-0468-5","volume":"17","author":"TM Maher","year":"2017","unstructured":"Maher TM, Molina-Molina M, Russell A-M, et al. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med. 2017;17(1):124.","journal-title":"BMC Pulm Med"},{"issue":"11","key":"1278_CR40","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1513\/AnnalsATS.201912-880OC","volume":"17","author":"ML Salisbury","year":"2020","unstructured":"Salisbury ML, Conoscenti CS, Culver DA, et al. Antifibrotic drug use in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020;17(11):1413\u201323. https:\/\/doi.org\/10.1513\/AnnalsATS.201912-880OC.","journal-title":"Ann Am Thorac Soc"},{"issue":"1","key":"1278_CR41","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12931-019-1161-4","volume":"20","author":"TM Maher","year":"2019","unstructured":"Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019;20(1):205. https:\/\/doi.org\/10.1186\/s12931-019-1161-4.","journal-title":"Respir Res"},{"issue":"6","key":"1278_CR42","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1159\/000490667","volume":"96","author":"TM Maher","year":"2018","unstructured":"Maher TM, Swigris JJ, Kreuter M, et al. Identifying barriers to idiopathic pulmonary fibrosis treatment: a survey of patient and physician views. Respiration. 2018;96(6):514\u201324.","journal-title":"Respiration"},{"issue":"3","key":"1278_CR43","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0954-6111(98)90282-7","volume":"92","author":"J Castellsagu\u00e9","year":"1998","unstructured":"Castellsagu\u00e9 J, Burgos F, Sunyer J, Barber\u00e0 JA, Roca J. Prediction equations for forced spirometry from European origin populations. Respir Med. 1998;92(3):401\u20137. https:\/\/doi.org\/10.1016\/S0954-6111(98)90282-7.","journal-title":"Respir Med"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-023-01278-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-023-01278-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T13:44:46Z","timestamp":1688564686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-023-01278-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1278"],"URL":"https:\/\/doi.org\/10.1007\/s40273-023-01278-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"26 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was supported and funded by Boehringer Ingelheim.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Maria Jesus Rodr\u00edguez Nieto has received funding for research (data monitoring boards), consulting fees and honoraria for presentations\/lectures and for being an advisor from Boehringer Ingelheim and Roche. Esteban Cano Jim\u00e9nez has received funding for research and consulting fees for presentations\/lectures and for being an advisor from Boehringer Ingelheim, Galapagos and Roche. Ana Dolores Romero Ortiz has received funding for research and consulting fees for presentations\/lectures and for being an advisor from Boehringer Ingelheim and Roche. Ana Villar has received consulting fees from Boehringer Ingelheim and Roche; fees for talks\/lectures from Boehringer Ingelheim, GlaxoSmithKline and Roche; and funding for conferences attendances and courses from Boehringer Ingelheim, Chiesi, Novartis and Roche. Marta Morros is a full-time employee of Adelphi Targis. Alba Ramon and Silvia Armengol are full-time employees of Boehringer Ingelheim Espa\u00f1a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical board of all participant hospitals. The Ethical Board of H. Fundaci\u00f3n Jim\u00e9nez D\u00edaz in Madrid, Spain acted as a reference ethical board. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent prior to their participation.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable (not idividual data reported).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets generated and\/or analysed during the current study are not publicly available because of participants privacy protection but are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"AR and SA were responsible for the original idea and study conceptualisation, methodology and supervision, as well as manuscript writing (review and editing). MM contributed in the formal analysis of results, data interpretation and data visualisation, and drafting the manuscript. EC, MJR, ADR and AV were involved in the study conceptualisation, methodology and investigation, as well as the review and writing of the results (review and editing). All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}